WAVE Life Sciences (NASDAQ:WVE) Stock Rating Upgraded by Truist Financial

WAVE Life Sciences (NASDAQ:WVE) was upgraded by Truist Financial to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

WVE has been the topic of a number of other research reports. B. Riley Financial lifted their price target on shares of WAVE Life Sciences from $19.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Leerink Partners restated an “outperform” rating on shares of WAVE Life Sciences in a report on Monday, December 8th. Canaccord Genuity Group raised their target price on WAVE Life Sciences from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered WAVE Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, WAVE Life Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $33.31.

WAVE Life Sciences Price Performance

Shares of NASDAQ:WVE opened at $12.30 on Wednesday. The business’s 50 day simple moving average is $13.24 and its 200 day simple moving average is $11.24. WAVE Life Sciences has a 1 year low of $5.28 and a 1 year high of $21.73. The company has a market capitalization of $2.32 billion, a P/E ratio of -10.08 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The firm had revenue of $17.25 million for the quarter, compared to analyst estimates of $15.68 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. On average, sell-side analysts anticipate that WAVE Life Sciences will post -1.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other WAVE Life Sciences news, insider Chris Francis sold 33,194 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $15.05, for a total value of $499,569.70. Following the completion of the sale, the insider directly owned 61,867 shares in the company, valued at approximately $931,098.35. This trade represents a 34.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kyle Moran sold 3,588 shares of WAVE Life Sciences stock in a transaction on Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $48,258.60. Following the completion of the sale, the chief financial officer directly owned 134,385 shares of the company’s stock, valued at approximately $1,807,478.25. This trade represents a 2.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 61,748 shares of company stock worth $907,809 in the last quarter. 23.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. GSK plc bought a new position in shares of WAVE Life Sciences during the fourth quarter valued at about $310,177,000. Darwin Global Management Ltd. bought a new stake in WAVE Life Sciences in the 4th quarter worth about $125,168,000. Federated Hermes Inc. grew its position in WAVE Life Sciences by 678,144.7% in the 3rd quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock worth $27,455,000 after purchasing an additional 3,750,140 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in WAVE Life Sciences by 83.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock valued at $125,927,000 after buying an additional 3,362,880 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after buying an additional 2,500,000 shares during the last quarter. 89.73% of the stock is owned by institutional investors.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Mizuho raised its price target on WVE from $22 to $27 and kept an “outperform” rating, representing a large upside vs. the stock’s current level; analyst upgrades like this can drive buying interest and raise investor confidence. Benzinga: Mizuho raises WVE target
• Positive Sentiment: Coverage summarizing Q4 drivers highlights what boosted WAVE in Q4 (revenue strength and institutional attention referenced by fund letters such as Loomis Sayles). Positive quarter commentary and signs of reaccelerating small-cap earnings help justify higher targets and attract momentum investors. Here’s What Boosted Wave Life Sciences Ltd. (WVE) in Q4
• Neutral Sentiment: Analyst roundups and media pieces (e.g., Globe and Mail) are discussing WVE alongside other healthcare names — these summaries increase visibility but do not by themselves change fundamentals. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Market-commentary pieces and stock reviews (AmericanBankingNews) have mentioned WVE alongside peers; useful for context but not a clear directional catalyst. Reviewing BioAtla & WAVE Life Sciences
• Neutral Sentiment: Reports flagged unusually high options activity and a reported increase in short-interest for March, but the published short-interest figures appear inconsistent (0 shares / NaN changes), suggesting a reporting/data error — watch for clarified filings before treating this as a bearish signal. WAVE Life Sciences Target of Unusually High Options Trading

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.